COVAD survey 2 long-term outcomes: unmet need and protocol.

Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O'Callaghan A, Nune A, Knitza J, Kuwana M, GutiƩrrez CT, Caballero-Uribe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, COVAD Study Group

Rheumatol Int - (-) - [2022-08-14; online 2022-08-14]

Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.

Category: Health

Type: Journal article

PubMed 35964271

DOI 10.1007/s00296-022-05157-6

Crossref 10.1007/s00296-022-05157-6

pii: 10.1007/s00296-022-05157-6


Publications 7.1.3